Results 41 to 50 of about 15,810 (189)
Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites.
Jean-François Timsit +14 more
doaj +1 more source
Objectives: To provide a descriptive analysis of the in vitro antimicrobial susceptibility testing results for all 39,661 Pseudomonas aeruginosa isolates collected by the ATLAS global surveillance programme data from 2020 to 2024 with a focus on ...
Mark A. Estabrook +3 more
doaj +1 more source
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Nicolau, David P +9 more
core +1 more source
Background: Complicated urinary tract infection (cUTI) is often associated with drug-resistant pathogens and requires therapy with broad-spectrum antibiotics.
Guan-Jhou Chen +5 more
doaj +1 more source
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion. [PDF]
Ceftolozane/tazobactam is a key antibiotic for Pseudomonas aeruginosa infections. Our objective was to determine whether continuous infusion (CI) of ceftolozane/tazobactam can achieve aggressive pharmacokinetic/pharmacodynamic (PK/PD) targets that ...
Cojutti PG +7 more
europepmc +2 more sources
Objectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations
María Fernández-Billón +9 more
doaj +1 more source
Pharmacokinetics of ceftolozane-tazobactam during prolonged intermittent renal replacement therapy
Background: Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely.
Regli, Adrian +8 more
core +1 more source
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom +9 more
doaj +1 more source
Activity of Ceftolozane–Tazobactam against Burkholderia pseudomallei [PDF]
We investigated the in vitro activity of a novel fifth-generation cephalosporin–tazobactam combination, ceftolozane–tazobactam against Burkholderia pseudomallei, the etiological agent of melioidosis. Using both disc diffusion and minimum inhibitory concentration (MIC) strip techniques against 56 clinical isolates and an national collection of type ...
Slack, Andrew +4 more
openaire +4 more sources
Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. In particular, bloodstream infection (BSI) is associated with a high rate of morbidity and mortality.
Henderson, A. +3 more
core +1 more source

